Aerie Pharmaceuticals, Inc. (AERI)
| Market Cap | 798.77M |
| Revenue (ttm) | 85.77M |
| Net Income (ttm) | -175.94M |
| Shares Out | 46.11M |
| EPS (ttm) | -3.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $16.83 |
| Previous Close | $16.82 |
| Change ($) | 0.01 |
| Change (%) | 0.06% |
| Day's Open | 16.50 |
| Day's Range | 16.19 - 17.01 |
| Day's Volume | 69,742 |
| 52-Week Range | 9.01 - 21.30 |
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie (AERI) delivered earnings and revenue surprises of -4.35% and -1.64%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie (AERI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
Aerie (AERI) delivered earnings and revenue surprises of -5.33% and 13.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript
Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript
Aerie (AERI) delivered earnings and revenue surprises of 19.75% and 4.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an excl...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2020 Results - Earnings Call Transcript
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Aerie has 2 marketed products and decent pipeline after a recent acquisition.
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript
About AERI
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is al... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Oct 25, 2013 |
| CEO Vicente Anido | Employees 365 |
| Stock Exchange NASDAQ | Ticker Symbol AERI |
Financial Performance
In 2020, AERI's revenue was $83.14 million, an increase of 18.96% compared to the previous year's $69.89 million. Losses were -$183.10 million, -8.26% less than in 2019.
Analyst Forecasts
According to 13 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 27.25, which is an increase of 61.91% from the latest price.